Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AMPH with free AI briefings, catalyst countdowns, and dilution alerts.

AMPH · Amphastar Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$234.5M Cash on Hand
CF+ Cash Runway
Follow AMPH by email Get an email when AMPH reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AMPH, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Hyaluronidase
FDA approved Oct 2004 · Amphadase
Allergic Skin Reaction Phase 2 · NCT01689363 Completed
Albuterol Asthma Phase 3 · NCT00634829 Terminated
Epinephrine HFA-MDI (E004) Asthma Phase 3 · NCT01737905 Completed
E004 (Epinephrine Inhalation Aerosol) HFA-MDI Asthma Phase 3 · NCT01460511 Completed
albuterol HFA (Armstrong's) Asthma Phase 3 · NCT00635505 Terminated
Albuterol Sulfate Inhalation Aerosol Asthma Phase 3 · NCT00634517 Terminated
Armstrong Albuterol Sulfate Inhalation Aerosol Asthma Phase 3 · NCT00634517 Terminated
E004 (epinephrine inhalation aerosol), 125 mcg Asthma Phase 1/2 · NCT01025648 Terminated
Epinephrine Inhalation Aerosol, HFA Asthma Phase 1/2 · NCT01188577 Completed
Histamine Allergic Skin Reaction Phase 2 · NCT01689363 Completed
Proventil-HFA Asthma Phase 2 · NCT01189396 Completed
Albuterol Sulfate Asthma Phase 2 · NCT02210806 Completed
A006 Asthma Phase 2 · NCT01189396 Completed
Arm T2: Primatene Mist HFA Asthma Phase 2 · NCT01255709 Completed
Arm T1: Primatene Mist HFA Asthma Phase 2 · NCT01255709 Completed
Arm T Epinephrine Inhalation Aerosol HFA, 125… Asthma Phase 1/2 · NCT01737892 Terminated

Also used in these trials (approved or third-party drugs, not AMPH's own candidates): Epinephrine Inhalation, Insulin Aspart.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AMPH holds $234.5M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AMPH files for a raise →

👥 Who Owns AMPH

Insiders 25% Institutions (312 holders) 67.6% Public and other holders 7.4%
HolderTypeShares% of sharesAs of
Jack Y. Zhang
CEO & CHIEF SCIENTIFIC OFFICER, Director · +149,472 options
Insider 9,817,731 23.02% 2026-03-15
Dimensional Fund Advisors LP Institution (13G, 5%+) 2,305,107 5.40% 2026-06-30
Rong Zhou
SENIOR EVP, PRODUCTION CENTER · +100,765 options
Insider 174,203 0.41% 2026-09-16
William J Peters
CFO, EVP & TREASURER, Director · +196,578 options
Insider 167,076 0.39% 2026-11-04
Howard Lee
Director · +17,365 options
Insider 159,350 0.37% 2026-06-01
Yakob Liawatidewi
EVP CORP ADMIN CENTER, Director · +73,126 options
Insider 124,351 0.29% 2026-03-15
Floyd F. Petersen
Director
Insider 71,368 0.17% 2025-12-11
Michael A Zasloff
Director · +17,365 options
Insider 37,667 0.09% 2026-06-01
Diane G. Gerst
Director · +17,365 options
Insider 31,899 0.07% 2026-06-01
Richard K Prins
Director · +17,365 options
Insider 29,625 0.07% 2026-08-11
Gayle Deflin
Director · +17,365 options
Insider 19,057 0.04% 2026-06-01
David Russell Gaugh
Director · +31,352 options
Insider 14,447 0.03% 2026-06-01

Share count 42,652,154 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AMPH picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AMPH and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.